Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone

Blood Cells, Molecules, and Diseases

Volumn 45, Issue 2, 2010, Pages 136-139

  Lai, Maria Eliana ^a   Grady, Robert W ^b   Vacquer, Stefania ^a   Pepe, Alessia ^c   Carta, Maria Paola ^a   Bina, Patrizio ^a   Sau, Franco ^d   Cianciulli, Paolo ^e   Maggio, Aurelio ^f   Galanello, Renzo ^a   Farci, Patrizia ^d  

^a Osp Regionale per le Microcitemie   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Combined iron chelation; Iron overload; Iron induced cardiomyopathy; Thalassaemia major

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFERIPRONE; DEFEROXAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRITIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; EVENING DOSAGE; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT;

ADULT; BETA-THALASSEMIA; CARDIOMYOPATHIES; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PROSPECTIVE STUDIES; PYRIDONES; SURVIVAL RATE;

EID: 77955274109     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.05.005     Document Type: Article

References (23)

1. Zurlo M.G., De Stefano P., Borgna-Pignatti C., et al. Survival and causes of death in thalassaemia major. Lancet 1989, 2:27-30.
2. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
3. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
4. Hershko C., Capellini M.D., Galanello R., Piga A., Tognoni G., Masera G. Purging iron from the heart. Br. J. Haematol. 2004, 125:545-551.
5. Grady R.W., Giardina P.J. Iron chelation: rationale for combination therapy. Iron Chelators. New Development Strategies 2000, 293-310. The Saratoga Group, Ponte Verde Beach, Fl. D.G. Badman, R.J. Bergeron, G.M. Brittenham (Eds.).
6. Wonke B., Wright C., Hoffbrand A.V. Combination therapy with deferiprone and desferrioxamine. Br. J. Haematol. 1998, 103:361-364.
7. Aydinok Y., Nisli G., Kavakli K. Alternate use of deferiprone and desferrioxamine in primary school children with thalassemia major. Br. J. Haematol. 1999, 106:252-253.
8. Sahn D.J., De Maria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
9. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 1989, 2:358-367.
10. *. Eur. J. Haematol. 2006, 76:183-192.
11. * cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J. Magn. Reson. Imaging 2006, 23:662-668.
12. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J. Med. 1994, 331:567-573.
13. Miskin H., Yaniv I., Berant M., Hershko C., Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur. J. Haematol. 2003, 70:398-403.
14. Davis B.A., Porter J.B. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000, 95:1229-1236.
15. Hoffbrand A.V., Cohen A., Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003, 102:17-24.
16. Piga A., Gaglioti C., Fogliacco E., Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003, 88:489-496.
17. Borgna-Pignatti C., Capellini M.D., De Stefano P., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107:3733-3737.
18. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516-520.
19. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:3738-3744.
20. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., Koussa S., Khoriaty A.I., Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 2003, 121:187-189.
21. Origa R., Bina P., Agus A., et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005, 90:1309-1314.
22. Tanner M.A., Galanello R., Dessi C., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-1884.
23. Link G., Konijn A.M., Breuer W., Cabantchik Z.I., Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and iron-loaded rat heart cells in culture. J. Lab. Clin. Med. 2001, 138:130-138.